© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lisa Astor is the Associate Editorial Director for Targeted Oncology. Astor received her Bachelor of Arts in English Literature from New York University.
September 28, 2021
Encouraging results have been reported from the phase 2 Guidance-01 clinical trial.
According to Tycel Jovelle Phillips, MD, the study of venetoclax in combination with the R2 regimen will be expanded to include 50 patients with mantle cell lymphoma without a TP53 mutation.
September 26, 2021
According to Eliza A. Hawkes, MD, the phase 2 1st FLOR trial showed the positive efficacy of frontline nivolumab in combination with rituximab.
Treatment with larotrectinib in patients with various subtypes of salivary gland tumors led to a high rate early and durable responses.